JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners
This article was originally published in Scrip
Executive Summary
Discussions with companies during last month's 34th Annual J.P. Morgan Healthcare Conference in San Francisco revealed that immuno-oncology remains as hot as ever with developers of targeted therapeutics shifting their focus to immunotherapies or agents that can be combined with the immune system-harnessing treatments for cancer.